142 related articles for article (PubMed ID: 10549730)
1. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
Fareed J; Haas S; Sasahar A
Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
[TBL] [Abstract][Full Text] [Related]
2. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
4. Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery.
Lassen MR; Backs S; Borris LC; Kaltoft-Sørenson M; Coff-Ganes H; Jeppesen E
Semin Thromb Hemost; 1999; 25 Suppl 3():79-82. PubMed ID: 10549720
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
Davidson BL
Semin Thromb Hemost; 1999; 25 Suppl 3():107-12. PubMed ID: 10549725
[TBL] [Abstract][Full Text] [Related]
6. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
[TBL] [Abstract][Full Text] [Related]
8. Production and chemical processing of low molecular weight heparins.
Linhardt RJ; Gunay NS
Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins: are they different?
Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
[TBL] [Abstract][Full Text] [Related]
10. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
11. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis.
Kaiser B; Kirchmaier CM; Breddin HK; Fu K; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():35-42. PubMed ID: 10549714
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Jeske W; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective.
Gulba D
Semin Thromb Hemost; 1999; 25 Suppl 3():123-7. PubMed ID: 10549727
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolic prophylaxis in orthopedic surgery: knee surgery.
Planés A; Vochelle N; Fafola M
Semin Thromb Hemost; 1999; 25 Suppl 3():73-7. PubMed ID: 10549719
[TBL] [Abstract][Full Text] [Related]
15. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH).
Holzheimer RG
Eur J Med Res; 2004 Mar; 9(3):150-70. PubMed ID: 15096326
[TBL] [Abstract][Full Text] [Related]
19. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
20. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
